INC Research (NDAQ:INCR) has been downgraded from Buy to Hold in a statement by Suntrust Robinson earlier today.
- Updated: March 20, 2017
Suntrust Robinson has downgraded INC Research (NDAQ:INCR) from Buy to Hold in a statement released on Monday March 20, 2017.
Boasting a price of $44.30, INC Research (NDAQ:INCR) traded 0.00% even on the day. With the last close down -6.57% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the date range. INC Research has recorded a 50-day average of $50.39 and a two hundred day average of $48.54. Volume of trade was down over the average, with 0 shares of INCR changing hands under the typical 566,549
With a total market value of $0, INC Research has price-earnings ratio of 22.34 with a one year low of $36.70 and a one year high of $57.11 .
A total of 7 analysts have released a research note on INCR. Three analysts rating the company a strong buy, four analysts rating the company a buy, three analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a one year target of $52.43.
More About INC Research (NDAQ:INCR)
INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company's Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company's Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.